These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17356951)

  • 41. [Surgical treatment of an advanced GIST the age of imatinib].
    Fernández JA; Parrilla P
    Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments.
    Reynoso D; Trent JC
    Curr Opin Oncol; 2010 Jul; 22(4):330-5. PubMed ID: 20520542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].
    Poveda A; Artigas V; Casado A; Cervera J; García Del Muro X; Antonio López-Guerrero J; López-Pousa A; Maurel J; Ortega L; Ramos R; Romero I; Safont MJ; Martín J;
    Cir Esp; 2008 Oct; 84 Suppl 1():1-21. PubMed ID: 19087862
    [No Abstract]   [Full Text] [Related]  

  • 44. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
    De Giorgi U
    J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
    [No Abstract]   [Full Text] [Related]  

  • 45. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
    Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
    ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
    Parikh PM; Gupta S
    Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
    Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of gastrointestinal stromal tumor (GIST)--review of the literature and a case report].
    Geraci G; Li Volsi F; Pisello F; Sciumè C; Cajozzo M; Cavaleri C; Modica G
    Ann Ital Chir; 2005; 76(4):377-80; discussion 381. PubMed ID: 16550875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effective neoadjuvant therapy prior to metastasectomy: a new paradigm.
    Schulick RD
    Ann Surg; 2007 Mar; 245(3):353-4. PubMed ID: 17435540
    [No Abstract]   [Full Text] [Related]  

  • 52. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Gastrointestinal stromal tumors: case reports and review of the literature].
    Bronzino P; Colombini M; Ferro A; Gambetta G; Gennaro M; Ivaldi L; Revetria P
    G Chir; 2008; 29(1-2):33-7. PubMed ID: 18252146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imatinib in gastrointestinal stromal tumor: does treatment duration matter?
    Adenis A; Penel N; Blay JY
    Oncology; 2009; 77(3-4):157-61. PubMed ID: 19729974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis.
    Al-Moundhri MS; Al-Thahli K; Al-Kindy S; Salam J; Rao L
    Saudi Med J; 2006 Oct; 27(10):1585-7. PubMed ID: 17013488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 58. [Surgical treatment of relapsing metastatic stromal tumor of the gastrointestinal tract].
    Stilidi IS; Arkhiri PP; Nikulin MP
    Vopr Onkol; 2011; 57(4):508-12. PubMed ID: 22191244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phenomenal response to treatment by an advanced tumour.
    Rahman SH; Roy A; Leahy M; Guillou PJ; Toogood GJ
    Gut; 2004 Nov; 53(11):1582, 1616. PubMed ID: 15479675
    [No Abstract]   [Full Text] [Related]  

  • 60. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.